BHB-810

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameBHB-810

Drug Alias NameBHB810BHB-810

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload

Mechanisms of ActionAnti-Cadherin-17DNA topoisomerase I inhibitors

TargetsCadherin-17DNA topoisomerase I

Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesBighat Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesBighat Biosciences Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A